Key terms

About BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BHC news

Nov 18 8:56am ET Bausch Health, Salix to present RED-C Phase 3 study design Nov 18 8:55am ET Bausch Health announces CABTREO receives positive reimbursement recommendations Nov 03 2:53am ET Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale Nov 01 6:28am ET Bausch Health Companies (BHC) Receives a Hold from RBC Capital Oct 31 3:45pm ET Bausch Health Companies: Hold Rating Amid Mixed Financial Performance and Strategic Uncertainty Oct 31 9:02am ET Evercore ISI Keeps Their Hold Rating on Bausch Health Companies (BHC) Oct 31 7:19am ET Truist Financial Keeps Their Hold Rating on Bausch Health Companies (BHC) Oct 31 7:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), LivaNova (LIVN) and Bausch Health Companies (BHC) Oct 31 12:45am ET Bausch Health Reports Growth Amid Improved Financials Oct 30 4:46pm ET Bausch Health Reports Strong Growth in Q3 2024 Oct 30 3:05pm ET Bausch Health options imply 10.2% move in share price post-earnings Oct 24 6:48am ET RBC Capital Remains a Hold on Bausch Health Companies (BHC) Oct 23 11:35am ET Bausch Health price target raised to $10 from $8.50 at RBC Capital Oct 18 2:45pm ET Bausch Health call volume above normal and directionally bullish Oct 17 4:45pm ET Bausch Health turns down bondholders’ debt proposals, WSJ reports Oct 15 8:46am ET Galecto announces the appointment of Wechsler to its Board of Directors Oct 15 8:17am ET Evercore ISI Reaffirms Their Hold Rating on Bausch Health Companies (BHC) Oct 14 12:13pm ET M&A News: TPG and Blackstone Could Eye Joint Bid for Bausch + Lomb (NYSE:BLCO) Oct 14 5:45am ET TPG, Blackstone teaming for Bausch + Lomb bid, may be up to $25/share, FT says Sep 18 1:30pm ET Bausch Health call volume above normal and directionally bullish Sep 18 12:00pm ET Bausch Health rises 10.1% Sep 18 9:40am ET Unusually active option classes on open September 18th Sep 17 9:00am ET B+L sale would be ‘very positive’ for Bausch Health, says Jefferies Sep 17 8:15am ET Buy Rating Reaffirmed for Bausch Health on Prospective Bausch + Lomb Sale and Value Unlocking Sep 16 12:31pm ET M&A News: Bausch+Lomb (NYSE:BLCO) Potentially Exploring Sale Amid Parent Company’s Debt Struggles Sep 16 9:51am ET Bausch Health rises 7.4% Sep 16 9:00am ET Wells says a potential Bausch + Lomb sale would make sense given valuation Sep 16 8:45am ET Bausch + Lomb mulls sale, Financial Times reports Sep 11 7:16am ET Bausch Health announces Health Canada approval of CABTREO topical treatment

BHC Financials

1-year income & revenue

Key terms

BHC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BHC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms